-
Je něco špatně v tomto záznamu ?
The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome
I. Marková, H. Malínská, M. Hüttl, D. Miklánková, O. Oliyarnyk, M. Poruba, Z. Rácová, L. Kazdová, R. Večeřa
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
PubMed Central
od 2020
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- anticholesteremika škodlivé účinky MeSH
- antioxidancia farmakologie MeSH
- atorvastatin škodlivé účinky MeSH
- diabetes mellitus 2. typu chemicky indukované farmakoterapie patologie MeSH
- hypercholesterolemie krev MeSH
- hyperlipidemie farmakoterapie MeSH
- kombinovaná farmakoterapie MeSH
- krysa rodu rattus MeSH
- metabolický syndrom farmakoterapie genetika patologie MeSH
- modely nemocí na zvířatech MeSH
- oxidační stres účinky léků MeSH
- silymarin farmakologie MeSH
- triglyceridy krev MeSH
- zánět farmakoterapie MeSH
- zvířata MeSH
- Check Tag
- krysa rodu rattus MeSH
- mužské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
Hypolipidemic and cardioprotective effects of statins can be associated with the development of myopathies and new-onset type 2 diabetes. These adverse effects may be related to increased oxidative stress. The plant extract silymarin (SM) is known for its antioxidant and anti-inflammatory actions. We tested the hypothesis that the combination of atorvastatin (ATV) with SM could improve therapy efficacy and eliminate some negative effects of statin on hypertriglyceridemia-induced metabolic disorders. Hereditary hypertriglyceridemic rats were fed a standard diet for four weeks without supplementation; supplemented with ATV (5 mg/kg b. wt./day) or a combination of ATV with 1 % micronized SM (ATV+SM). ATV treatment elevated plasma levels of HDL-cholesterol (p<0.01), glucose and insulin and decreased triglycerides (p<0.001). The combination of ATV+SM led to a significant reduction in insulin, an improvement of glucose tolerance, and the hypolipidemic effect was enhanced compared to ATV alone. Furthermore, ATV supplementation increased skeletal muscle triglycerides but its combination with SM decreased triglycerides accumulation in the muscle (p<0.05) and the liver (p<0.01). In the liver, ATV+SM treatment increased the activities of antioxidant enzymes, glutathione and reduced lipid peroxidation (p<0.001). The combined administration of ATV with SM potentiated the hypolipidemic effect, reduced ectopic lipid accumulation, improved glucose metabolism, and increased antioxidant and anti-inflammatory actions. Our results show that SM increased the effectiveness of statin therapy in a hypertriglyceridemic rat model of metabolic syndrome.
Citace poskytuje Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22000819
- 003
- CZ-PrNML
- 005
- 20220202102812.0
- 007
- ta
- 008
- 220106s2021 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.934587 $2 doi
- 035 __
- $a (PubMed)33453720
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Marková, Irena $7 xx0161888 $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 245 14
- $a The combination of atorvastatin with silymarin enhances hypolipidemic, antioxidant and anti-inflammatory effects in a rat model of metabolic syndrome / $c I. Marková, H. Malínská, M. Hüttl, D. Miklánková, O. Oliyarnyk, M. Poruba, Z. Rácová, L. Kazdová, R. Večeřa
- 504 __
- $a Literatura
- 520 9_
- $a Hypolipidemic and cardioprotective effects of statins can be associated with the development of myopathies and new-onset type 2 diabetes. These adverse effects may be related to increased oxidative stress. The plant extract silymarin (SM) is known for its antioxidant and anti-inflammatory actions. We tested the hypothesis that the combination of atorvastatin (ATV) with SM could improve therapy efficacy and eliminate some negative effects of statin on hypertriglyceridemia-induced metabolic disorders. Hereditary hypertriglyceridemic rats were fed a standard diet for four weeks without supplementation; supplemented with ATV (5 mg/kg b. wt./day) or a combination of ATV with 1 % micronized SM (ATV+SM). ATV treatment elevated plasma levels of HDL-cholesterol (p<0.01), glucose and insulin and decreased triglycerides (p<0.001). The combination of ATV+SM led to a significant reduction in insulin, an improvement of glucose tolerance, and the hypolipidemic effect was enhanced compared to ATV alone. Furthermore, ATV supplementation increased skeletal muscle triglycerides but its combination with SM decreased triglycerides accumulation in the muscle (p<0.05) and the liver (p<0.01). In the liver, ATV+SM treatment increased the activities of antioxidant enzymes, glutathione and reduced lipid peroxidation (p<0.001). The combined administration of ATV with SM potentiated the hypolipidemic effect, reduced ectopic lipid accumulation, improved glucose metabolism, and increased antioxidant and anti-inflammatory actions. Our results show that SM increased the effectiveness of statin therapy in a hypertriglyceridemic rat model of metabolic syndrome.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a anticholesteremika $x škodlivé účinky $7 D000924
- 650 _2
- $a antioxidancia $x farmakologie $7 D000975
- 650 _2
- $a atorvastatin $x škodlivé účinky $7 D000069059
- 650 _2
- $a diabetes mellitus 2. typu $x chemicky indukované $x farmakoterapie $x patologie $7 D003924
- 650 _2
- $a modely nemocí na zvířatech $7 D004195
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a hypercholesterolemie $x krev $7 D006937
- 650 _2
- $a hyperlipidemie $x farmakoterapie $7 D006949
- 650 _2
- $a zánět $x farmakoterapie $7 D007249
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a metabolický syndrom $x farmakoterapie $x genetika $x patologie $7 D024821
- 650 _2
- $a oxidační stres $x účinky léků $7 D018384
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 _2
- $a silymarin $x farmakologie $7 D012838
- 650 _2
- $a triglyceridy $x krev $7 D014280
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Malínská, Hana $7 xx0158953 $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Hüttl, Martina $7 xx0230591 $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Miklánková, Denisa. $7 xx0268627 $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Oliyarnyk, Olena $7 xx0095365 $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Poruba, Martin $7 xx0230224 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Rácová, Zuzana $7 xx0109661 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 700 1_
- $a Kazdová, Ludmila, $d 1938- $7 xx0053119 $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- 700 1_
- $a Večeřa, Rostislav, $d 1965- $7 mzk2004236742 $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 70, č. 1 (2021), s. 33-43
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33453720 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y p $z 0
- 990 __
- $a 20220106 $b ABA008
- 991 __
- $a 20220202102800 $b ABA008
- 999 __
- $a ok $b bmc $g 1755650 $s 1151965
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 70 $c 1 $d 33-43 $e 20210114 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- LZP __
- $b NLK118 $a Pubmed-20220106